NCT03133195View on ClinicalTrials.gov

The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 17, 2017

Primary Completion Date

June 1, 2022

Study Completion Date

July 1, 2023

Conditions
Unstable Intertrochanteric FracturePertrochanteric Fracture of Femur, Closed
Interventions
DRUG

Teriparatide

Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)

DRUG

Placebo

Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)

DIETARY_SUPPLEMENT

Calcium supplement

1000 mg/day of elemental calcium

DIETARY_SUPPLEMENT

Vitamin D

20,000 IU/week of vitamin D2

Trial Locations (1)

10330

Faculty of Medicine Chulalongkorn University, Bangkok

All Listed Sponsors
lead

King Chulalongkorn Memorial Hospital

OTHER

NCT03133195 - The Effect of Teriparatide on Bone Union in Unstable Intertrochanteric Fracture Patients Treated With PFNA | Biotech Hunter | Biotech Hunter